CA2871535A1 - Biomarkers for the treatment of hepatocellular carcinoma - Google Patents

Biomarkers for the treatment of hepatocellular carcinoma Download PDF

Info

Publication number
CA2871535A1
CA2871535A1 CA2871535A CA2871535A CA2871535A1 CA 2871535 A1 CA2871535 A1 CA 2871535A1 CA 2871535 A CA2871535 A CA 2871535A CA 2871535 A CA2871535 A CA 2871535A CA 2871535 A1 CA2871535 A1 CA 2871535A1
Authority
CA
Canada
Prior art keywords
biomarker
tcf
subject
level
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA2871535A
Other languages
English (en)
French (fr)
Inventor
Miran Kim
Jack R. Wands
Sarah BESEME
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Celgene Corp
Original Assignee
Rhode Island Hospital
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital, Celgene Corp filed Critical Rhode Island Hospital
Publication of CA2871535A1 publication Critical patent/CA2871535A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2871535A 2012-01-13 2013-01-11 Biomarkers for the treatment of hepatocellular carcinoma Withdrawn CA2871535A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586672P 2012-01-13 2012-01-13
US61/586,672 2012-01-13
PCT/US2013/021197 WO2013106686A1 (en) 2012-01-13 2013-01-11 Biomarkers for the treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
CA2871535A1 true CA2871535A1 (en) 2013-07-18

Family

ID=47604231

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871535A Withdrawn CA2871535A1 (en) 2012-01-13 2013-01-11 Biomarkers for the treatment of hepatocellular carcinoma

Country Status (8)

Country Link
US (1) US8901110B2 (enExample)
EP (1) EP2802877A1 (enExample)
JP (1) JP2015504677A (enExample)
CN (1) CN104737021A (enExample)
AU (1) AU2013202104B2 (enExample)
CA (1) CA2871535A1 (enExample)
MX (1) MX2014008388A (enExample)
WO (1) WO2013106686A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
RU2611007C2 (ru) 2011-03-11 2017-02-17 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
WO2015085172A2 (en) * 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
CN103645259B (zh) * 2013-12-12 2015-03-11 深圳海王药业有限公司 一种同时测定泊马度胺及其有关物质的方法
JP2017533727A (ja) * 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN108048568B (zh) * 2017-12-25 2021-02-02 贵州省人民医院 Plcd4基因作为胃腺癌转移诊断标志物的用途
CN109266747B (zh) * 2018-09-21 2021-07-27 中国医学科学院北京协和医院 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用
CN113194934B (zh) * 2018-10-14 2025-02-25 蓝腾制药公司 使用隐陡头菌素和生物标志物治疗实体肿瘤癌症的方法
CA3121273A1 (en) * 2018-11-29 2020-06-04 Trillium Therapeutics Inc. Biomarkers for cd47 blockade therapy
CN116064810A (zh) * 2022-11-10 2023-05-05 杭州医学院 CD24作为Hippo通路失活亚型肝细胞癌生物标志物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1166651C (zh) * 2001-06-08 2004-09-15 北京大学药学院 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
WO2011109237A2 (en) * 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap

Also Published As

Publication number Publication date
AU2013202104A1 (en) 2013-08-01
EP2802877A1 (en) 2014-11-19
AU2013202104B2 (en) 2015-11-26
JP2015504677A (ja) 2015-02-16
WO2013106686A1 (en) 2013-07-18
MX2014008388A (es) 2014-11-14
US20130183675A1 (en) 2013-07-18
CN104737021A (zh) 2015-06-24
US8901110B2 (en) 2014-12-02

Similar Documents

Publication Publication Date Title
US8901110B2 (en) Use of biomarkers in methods for the treatment of hepatocellular carcinoma
JP7142612B2 (ja) びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法
US20170242014A1 (en) Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
US20180231561A1 (en) Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
Werner et al. Expression of epithelial mesenchymal transition and cancer stem cell markers in circulating tumor cells
JP2020523022A (ja) 免疫療法に反応する肝細胞癌のクラスの検出および治療方法
CN103026229B (zh) 用于治疗银屑病的生物标志物
JP2025111438A (ja) イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法
CN101990577A (zh) 鉴定肺病药物开发的新途径
Xie et al. Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma
US20160153998A1 (en) Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
US20120329061A1 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients
JP7177096B2 (ja) 乳癌を検出する方法
Jiang et al. TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas
Vanhove et al. Biopsy-derived intestinal epithelial cell cultures for pathway-based stratification of patients with inflammatory bowel disease
Liu et al. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients
AU2017299513A1 (en) Biomarkers for detection and treatment of mast cell activity-associated disorders
Pan et al. Elevated expression of yes‑associated protein is associated with the malignant status and prognosis of laryngeal squamous cell carcinoma
US20110111396A1 (en) Biomarkers for monitoring the treatment by quinazolinone compounds
JP5140808B2 (ja) 消化管間質腫瘍（ｇｉｓｔ）を患う患者の予後を予測するために使用する腫瘍マーカー及びキット並びにフェチンの使用方法
Lammert et al. PAX8‐positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles–A clinicopathologic study of 101 consecutive cases with next‐generation sequencing in 20 cases
Rodrigues Cancer stem cells in liver cancer
JP2024511601A (ja) 免疫療法を評価するための手段及び方法
Foglia STUDY ON THE ROLE OF HYPOXIA-INDUCIBLE FACTOR 2α AND SERPINB3 IN RELATION TO LIVER CARCINOGENESIS
Corrò Dissecting tumor heterogeneity and cancer stem cell properties in clear cell renal cell carcinoma

Legal Events

Date Code Title Description
AZWI Withdrawn application

Effective date: 20170824